
QF-Pro®may significantly boost immunotherapy response rates in lung cancer
Our new trial results, published in the Journal of Clinical Oncology show that QF-Pro® identifies 24.5% of non-small cell lung cancer patients, who have low PD-L1 expression scores in fact have significant PD-1/PD-L1 interaction states. These patients are currently missing life saving treatments due to incorrect patient stratification.